Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening

被引：46

作者：

Usui, Taikou ^{[1
]}

Ban, Hyun Seung ^{[1
]}

Kawada, Junpei ^{[1
]}

Hirokawa, Takatsugu ^{[2
]}

Nakamura, Hiroyuki ^{[1
]}

机构：

[1] Gakushuin Univ, Fac Sci, Dept Chem, Tokyo 1718588, Japan

[2] Inst Adv Ind Sci & Technol AIST, Computat Biol Res Ctr, Tokyo 1350064, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 01期

关键词：

D O I：

10.1016/j.bmcl.2007.10.084

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of indenopyrazoles 8 and 9 were designed and synthesized as EGFR tyrosine kinase inhibitors by in silico high-throughput screening. Compounds 8b and 8d showed significant inhibition of A431 cell growth (GI(50) = 0.062 and 0.057 mu M, respectively). Compounds 8b and 9a showed inhibitory activity toward both EGFR and VEGFR-2 (KDR) tyrosine kinases, whereas 8d inhibited VEGFR-2 tyrosine kinase, exclusively. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：285 / 288

页数：4

共 27 条

[11] Developing inhibitors of the epidermal growth factor receptor for cancer treatment
Grünwald, V
Hidalgo, M
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12): : 851 - 867
[12] Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
Halgren, TA
Murphy, RB
Friesner, RA
Beard, HS
Frye, LL
Pollard, WT
Banks, JL
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) : 1750 - 1759
[13] HARRIS PA, 2005, J MED CHEM, V16, P10
[14] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
Kris, MG
Natale, RB
Herbst, RS
Lynch, TJ
Prager, D
Belani, CP
Schiller, JH
Kelly, K
Spiridonidis, H
Sandler, A
Albain, KS
Cella, D
Wolf, MK
Averbuch, SD
Ochs, JJ
Kay, AC
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16): : 2149 - 2158
[15] Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, EL
Sordella, R
Bell, DW
Godin-Heymann, N
Okimoto, RA
Brannigan, BW
Harris, PL
Driscoll, DR
Fidias, P
Lynch, TJ
Rabindran, SK
McGinnis, JP
Wissner, A
Sharma, SV
Isselbacher, KJ
Settleman, J
Haber, DA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) : 7665 - 7670
[16] Protein kinase inhibitors: The tyrosine-specific protein kinases
Lawrence, DS
Niu, JK
[J]. PHARMACOLOGY & THERAPEUTICS, 1998, 77 (02) : 81 - 114
[17] Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases
Nakamura, Hiroyuki
Sasaki, Yusuke
Uno, Masaharu
Yoshikawa, Tomohiro
Asano, Toru
Ban, Hyun Seung
Fukazawa, Hidesuke
Shibuya, Masabumi
Uehara, Yoshimasa
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (19) : 5127 - 5131
[18] Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern
Nugiel, DA
Vidwans, A
Etzkorn, AM
Rossi, KA
Benfield, PA
Burton, CR
Cox, S
Doleniak, D
Seitz, SP
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (24) : 5224 - 5232
[19] Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors
Nugiel, DA
Etzkorn, AM
Vidwans, A
Benfield, PA
Boisclair, M
Burton, CR
Cox, S
Czerniak, PM
Doleniak, D
Seitz, SP
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (09) : 1334 - 1336
[20] Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
Pérez-Soler, R
Chachoua, A
Hammond, LA
Rowinsky, EK
Huberman, M
Karp, D
Rigas, J
Clark, GM
Santabàrbara, P
Bonomi, P
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3238 - 3247

← 1 2 3 →